OOIR: Observatory of International Research

Papers

(The median citation count of New England Journal of Medicine is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine	11797
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine	8134
Dexamethasone in Hospitalized Patients with Covid-19	6981
Remdesivir for the Treatment of Covid-19 — Final Report	5468
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report	2667
Empagliflozin in Heart Failure with a Preserved Ejection Fraction	2546
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant	2309
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting	2167
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates	2126
Cytokine Storm	2098
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19	2028
Once-Weekly Semaglutide in Adults with Overweight or Obesity	1830
Lecanemab in Early Alzheimer’s Disease	1801
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant	1776
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination	1748
Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results	1746
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer	1712
New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race	1674
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19	1555
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months	1461
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19	1448
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma	1393
Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022	1370
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19	1346
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients	1332

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes	1329
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19	1326
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer	1284
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure	1217
Tirzepatide Once Weekly for the Treatment of Obesity	1198
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer	1191
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction	1188
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults	1186
Covid-19 Breakthrough Infections in Vaccinated Health Care Workers	1163
Colchicine in Patients with Chronic Coronary Disease	1152
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer	1146
Severe Covid-19	1138
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination	1131
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months	1116
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia	1109
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma	1098
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host	1086
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19	1080
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma	1076
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19	1064
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19	1057
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant	1015
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis	1006
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia	993
Sotorasib for Lung Cancers with KRAS p.G12C Mutation	991
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma	981
How Structural Racism Works — Racist Policies as a Root Cause of U.S. Racial Health Inequities	963
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis	961
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer	959
Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine	958
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine	932
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer	917
Empagliflozin in Patients with Chronic Kidney Disease	908
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel	887
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients	872
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19	870
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab	844
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis	843
Waning Immunity after the BNT162b2 Vaccine in Israel	841
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes	839
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants	828
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine	809
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19	781
Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination	774
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma	772
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer	770
Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting	767
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers	761
Donanemab in Early Alzheimer’s Disease	759
Trial of Psilocybin versus Escitalopram for Depression	754

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer	749
Benefits, Limits, and Risks of GPT-4 as an AI Chatbot for Medicine	744
Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients	739
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease	736
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents	729
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes	727
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia	727
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19	717
Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults	702
Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile	690
Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease	689
A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia	680
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19	680
Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons	677
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar	668
Pathophysiology of Inflammatory Bowel Diseases	666
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer	647
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination	641
Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine	640
Rethinking Covid-19 Test Sensitivity — A Strategy for Containment	627
Vaccine Breakthrough Infections with SARS-CoV-2 Variants	626
Breast Cancer Risk Genes — Association Analysis in More than 113,000 Women	618
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma	607
Racial Bias in Pulse Oximetry Measurement	603
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19	600
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer	599
Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest	594
Acquired Resistance to KRAS^G12C Inhibition in Cancer	591
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer	586
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma	575
New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications	565
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer	559
Avacopan for the Treatment of ANCA-Associated Vasculitis	551
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19	550
Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa	550
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes	549
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease	538
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant	534
Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines	527
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma	522
Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19	521
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma	516
Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection	514
Neutralizing Activity of BNT162b2-Elicited Serum	511
Evidence of Artemisinin-Resistant Malaria in Africa	511
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine	495
Diffuse Large B-Cell Lymphoma	495
Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer	494
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants	493
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer	493
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma	487
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer	485
Myocarditis after Covid-19 Vaccination in a Large Health Care Organization	483
REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19	478
Osteoarthritis of the Knee	474
Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients	472
A Bivalent Omicron-Containing Booster Vaccine against Covid-19	470
A Population-Based Study of Genes Previously Implicated in Breast Cancer	468
Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel	465
Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5	463
Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation	458
Teclistamab in Relapsed or Refractory Multiple Myeloma	451
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma	448
Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis	447
Endovascular Therapy for Acute Stroke with a Large Ischemic Region	445
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer	444
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer	444
Homologous and Heterologous Covid-19 Booster Vaccinations	441
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age	439
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women	437
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer	435
Migraine	435
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase	428
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19	427
Race and Genetic Ancestry in Medicine — A Time for Reckoning with Racism	425
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression	423
Microvascular Injury in the Brains of Patients with Covid-19	422
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer	416
Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections	414
Artificial Intelligence and Machine Learning in Clinical Medicine, 2023	412

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine	407
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes	406
Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure	400
100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care — Preliminary Report	398
Trends in Diabetes Treatment and Control in U.S. Adults, 1999–2018	396
Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS ^G12C Mutation	395
Surgery or Endovascular Therapy for Chronic Limb-Threatening Ischemia	395
Endometrial Cancer	393
Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke	391
SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia	389
Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines	387
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity	385
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma	385
SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons	383
Cryoballoon Ablation as Initial Therapy for Atrial Fibrillation	379
Effect of Salt Substitution on Cardiovascular Events and Death	377
Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension	375
Lobar or Sublobar Resection for Peripheral Stage IA Non–Small-Cell Lung Cancer	375
Protection against the Omicron Variant from Previous SARS-CoV-2 Infection	373
Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings	368
Trial of Endovascular Therapy for Acute Ischemic Stroke with Large Infarct	366
SARS-CoV-2 Variants in Patients with Immunosuppression	360
Trial of Endovascular Thrombectomy for Large Ischemic Strokes	359
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19	359
Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia	359
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH	358
Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease	358
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients	356
Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection	352
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3	349
Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer	348
Efficacy of Wolbachia-Infected Mosquito Deployments for the Control of Dengue	347
Hypothermic Machine Perfusion in Liver Transplantation — A Randomized Trial	347
Endovascular Therapy for Stroke Due to Basilar-Artery Occlusion	346
Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS	342
Atopic Dermatitis	342
Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination	340
Biologic Therapies for Severe Asthma	339
Genetically Modified Porcine-to-Human Cardiac Xenotransplantation	339
A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19	338
Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease	337
Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants	337
Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants	334
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk	334
Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron	334
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis	333
Wildfires, Global Climate Change, and Human Health	333
Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death	332
Pulmonary Arterial Hypertension	330
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer	328
Plasma Neutralization of the SARS-CoV-2 Omicron Variant	327
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition	326
The Clinician and Dataset Shift in Artificial Intelligence	325
SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination	324
Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant	324
Trial of Thrombectomy 6 to 24 Hours after Stroke Due to Basilar-Artery Occlusion	322
Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar	322
Maintaining Safety with SARS-CoV-2 Vaccines	322
A Randomized Trial Comparing Antibiotics with Appendectomy for Appendicitis	321
SARS-CoV-2 Variants and Vaccines	318
Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma	316
Current Causes of Death in Children and Adolescents in the United States	316
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer	315
Covid-19 Vaccines — Immunity, Variants, Boosters	314
Population Immunity and Covid-19 Severity with Omicron Variant in South Africa	312
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1	312
Physical Rehabilitation for Older Patients Hospitalized for Heart Failure	311
Long-Term Survival after Kidney Transplantation	307
A Pandemic within a Pandemic — Intimate Partner Violence during Covid-19	307
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma	306
Trial of Endovascular Treatment of Acute Basilar-Artery Occlusion	305
Protection by a Fourth Dose of BNT162b2 against Omicron in Israel	302
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial	301
Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2	301
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis	300
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico	295
Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk	294
Circadian Mechanisms in Medicine	294
Sotatercept for the Treatment of Pulmonary Arterial Hypertension	293
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis	293
Effect of Vaccination on Household Transmission of SARS-CoV-2 in England	290
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults	290
Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome	289
Transcatheter Repair for Patients with Tricuspid Regurgitation	289
Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants	284
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission	284
Women Physicians and Promotion in Academic Medicine	284
Long-Term Complications in Youth-Onset Type 2 Diabetes	283
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis	282
Childhood Cardiovascular Risk Factors and Adult Cardiovascular Events	281
Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes	280
New Horizons in the Treatment of Osteosarcoma	280
A Randomized Trial of Intravenous Alteplase before Endovascular Treatment for Stroke	279
Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents	279
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis	277